While its involvement in modulating response to HER2-targeted therapies like neratinib and lapatinib suggests its potential as a therapeutic target [84], further research is needed to fully elucidate SIRT1’s functions and to develop strategies for its modulation in HER2+ breast cancer treatment. The gene discussed is ERBB2; the disease is breast carcinoma.